

Use of *Apretude* for Pre-Exposure Prophylaxis in Transgender Men

Summary

- Data on the use of *Apretude* (long-acting cabotegravir, CAB LA) for pre-exposure prophylaxis (PrEP) in transgender men are currently unavailable.
- Important Safety Information and Boxed Warning can be found in the [Prescribing Information](#) and can also be accessed from the [Our HIV Medicines](#) section of viivhealthcare.com/us.

To access additional scientific information related to ViiV Healthcare medicines, visit the ViiV US Medical Portal at viivhcmmedinfo.com.



Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

This information is scientific and non-promotional in nature and is not intended for further distribution.

This information is not intended to offer recommendations for using this product in a manner inconsistent with its approved labeling. Please consult the Prescribing Information. For ViiV Healthcare to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 877-844-8872.

Selection of references follows principles of evidence-based medicine and, therefore, references may not be all inclusive.

